Cullinan Associates Inc. Has $10.16 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)

Cullinan Associates Inc. trimmed its position in Merck & Co., Inc. (NYSE:MRK) by 1.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 111,715 shares of the company’s stock after selling 1,241 shares during the quarter. Cullinan Associates Inc.’s holdings in Merck & Co., Inc. were worth $10,160,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of MRK. BancorpSouth Bank increased its holdings in Merck & Co., Inc. by 3.1% in the 3rd quarter. BancorpSouth Bank now owns 50,676 shares of the company’s stock valued at $4,266,000 after buying an additional 1,538 shares during the period. Lehman & Derafelo Financial Resources LLC increased its holdings in Merck & Co., Inc. by 5.1% in the 2nd quarter. Lehman & Derafelo Financial Resources LLC now owns 51,175 shares of the company’s stock valued at $4,381,000 after buying an additional 2,502 shares during the period. Nomura Holdings Inc. increased its holdings in Merck & Co., Inc. by 260.4% in the 3rd quarter. Nomura Holdings Inc. now owns 801,905 shares of the company’s stock valued at $67,143,000 after buying an additional 579,388 shares during the period. Pictet Asset Management Ltd. increased its holdings in Merck & Co., Inc. by 5.2% in the 3rd quarter. Pictet Asset Management Ltd. now owns 2,519,127 shares of the company’s stock valued at $212,060,000 after buying an additional 123,617 shares during the period. Finally, Ashburton Jersey Ltd increased its holdings in Merck & Co., Inc. by 0.4% in the 3rd quarter. Ashburton Jersey Ltd now owns 210,924 shares of the company’s stock valued at $17,756,000 after buying an additional 750 shares during the period. Institutional investors and hedge funds own 74.50% of the company’s stock.

Several equities research analysts have issued reports on the stock. Bank of America assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 price target on the stock. JPMorgan Chase & Co. set a $96.00 price target on shares of Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, October 10th. Morgan Stanley boosted their price target on shares of Merck & Co., Inc. from $90.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. Mizuho reissued a “buy” rating and issued a $100.00 price target on shares of Merck & Co., Inc. in a report on Monday, January 6th. Finally, Royal Bank of Canada initiated coverage on shares of Merck & Co., Inc. in a report on Monday, January 6th. They issued a “sector perform” rating and a $99.00 target price on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the company’s stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and a consensus price target of $95.69.

MRK opened at $91.54 on Thursday. The firm’s 50-day simple moving average is $89.80 and its 200-day simple moving average is $85.55. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.98 and a current ratio of 1.26. Merck & Co., Inc. has a twelve month low of $72.05 and a twelve month high of $92.64. The firm has a market cap of $228.96 billion, a price-to-earnings ratio of 21.09, a PEG ratio of 1.80 and a beta of 0.52.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 48.16%. The business had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. During the same quarter in the prior year, the firm earned $1.19 EPS. The firm’s quarterly revenue was up 14.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 5.15 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 8th. Stockholders of record on Monday, December 16th were issued a $0.61 dividend. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, December 13th. This represents a $2.44 annualized dividend and a dividend yield of 2.67%. Merck & Co., Inc.’s dividend payout ratio is presently 56.22%.

In related news, EVP Julie L. Gerberding sold 102,073 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $89.34, for a total transaction of $9,119,201.82. Following the transaction, the executive vice president now owns 106,099 shares in the company, valued at approximately $9,478,884.66. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.27% of the stock is currently owned by corporate insiders.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Cost of Debt

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.